<DOC>
	<DOCNO>NCT00028366</DOCNO>
	<brief_summary>Ritonavir ( RTV ) protease inhibitor ( PI ) commonly used increase drug level PIs HIV drug treatment . The purpose study compare combination drug include RTV 2 protease inhibitor ( PIs ) 2 combination include RTV another PI . This study also compare effectiveness , safety , tolerability , drug level blood anti-HIV drug combination .</brief_summary>
	<brief_title>Dual Versus Triple Protease Inhibitor Combinations , Including Ritonavir , HIV Infected People</brief_title>
	<detailed_description>A substantial proportion patient antiretroviral therapy achieve sustain suppression HIV viral load . Developing strategy improve response subsequent regimen important objective management patient HIV infection . Increasing potency regimen use pharmacoenhancer RTV interest . RTV use widely increase plasma concentration PIs , little efficacy tolerability data different RTV-enhanced PIs . The efficacy tolerability triple PI regimen compare dual PI regimens ; dual PI regimen also compare . In Step 1 , patient selectively randomize ( base prior exposure study drug ) enrol 1 3 study arm . Patients Arm A receive lopinavir ( LPV ) /RTV combination TDF 1 2 NRTIs ; patient Arm B receive fosamprenavir plus RTV combination TDF 1 2 NRTIs ; Arm C patient receive LPV/RTV plus fosamprenavir combination TDF 1 2 NRTIs . Because interim study result indicate mean PI level patient Arm C unacceptably low , Arm C patient either drop LPV/RTV add RTV drop fosamprenavir regimen . The study last 24 48 week . Medications clinical assessment blood collection perform 2 week prior entry , entry , Weeks 2 , 4 , 8 , 12 , 16 , 24 , 32 , 40 , 48 . Blood sample test amprenavir ( APV ) LPV pharmacokinetics collect Weeks 12 , 24 , 48 , confirm virologic failure visit . In substudy A5147S , intensive 12-hour pharmacokinetic sampling APV , LPV , RTV conduct . The first 20-25 patient enrol arm enrol substudy 14-28 day start study treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Note : Accrual A5143 A5147S discontinue . The study originally plan enroll 216 participant , 56 participant enrol time early termination enrollment interim review result . Inclusion Criteria Step 1 HIV infect Past antiHIV therapy consist least 1 PIcontaining regimen detectable viral load , least 1 year total antiHIV therapy experience Viral load 5000 copies/ml within 60 day prior screen stable antiHIV therapy least 12 week Agree use acceptable form contraception Exclusion Criteria More 7 day treatment LPV and/or 7 day treatment APV fosamprenavir HIV vaccine within 90 day study entry Experimental drug within 30 day study entry Cancer chemotherapy within 30 day study entry Drugs affect immune system within 30 day study entry Certain drug within 14 day study entry . Patients use drug might damage kidney within 7 day study entry allow . Midazolam within 7 day study entry Allergic sensitive study drug Excessive drug alcohol use Serious illness require treatment and/or hospitalization complete therapy , stable therapy least 14 day prior study entry Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
	<keyword>ABT 378</keyword>
	<keyword>tenofovir disoproxil</keyword>
	<keyword>VX-175</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>